These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15818764)

  • 1. Powerful HDL booster available OTC.
    Health News; 2005 Apr; 11(4):5. PubMed ID: 15818764
    [No Abstract]   [Full Text] [Related]  

  • 2. On call. In your January 2007 article on cholesterol, you said that no-flush niacin does not lower cholesterol levels. But my problem is low HDL cholesterol. Will no-flush niacin help my HDL even if it won't lower my LDL cholesterol?
    Simon HB
    Harv Mens Health Watch; 2007 Jun; 11(11):7-8. PubMed ID: 17644843
    [No Abstract]   [Full Text] [Related]  

  • 3. Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction.
    Davidson MH; Ballantyne CM
    Am J Cardiol; 2008 Apr; 101(8A):1B-2B. PubMed ID: 18375235
    [No Abstract]   [Full Text] [Related]  

  • 4. Ask the doctor. I tried taking niacin to increase my HDL but didn't like the flushing it caused. A friend told me about no-flush niacin, which works like a charm. Why not tell your readers about it?
    Lee T
    Harv Heart Lett; 2010 Mar; 20(7):8. PubMed ID: 20586132
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging.
    Jaffer FA
    J Am Coll Cardiol; 2009 Nov; 54(19):1795-6. PubMed ID: 19874993
    [No Abstract]   [Full Text] [Related]  

  • 6. [New drug against lipid disorders. HDL level rises 30%].
    MMW Fortschr Med; 2003 Sep; 145(39):51. PubMed ID: 14649076
    [No Abstract]   [Full Text] [Related]  

  • 7. Strategies for raising HDL cholesterol.
    Harv Heart Lett; 2001 Nov; 12(3):5-6. PubMed ID: 11724689
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
    März W
    MMW Fortschr Med; 2005 Apr; 147(14):14. PubMed ID: 15887675
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of dyslipoproteinemia risk factor. Lipid therapy must become multidimensional].
    MMW Fortschr Med; 2008 Jun; 150(26-27):52-3. PubMed ID: 18681233
    [No Abstract]   [Full Text] [Related]  

  • 11. Bibliography. Current world literature. HDL cholesterol.
    Curr Opin Cardiol; 2008 Jul; 23(4):426-9. PubMed ID: 18536113
    [No Abstract]   [Full Text] [Related]  

  • 12. Nicotinic acid in the treatment of hyperlipidaemia.
    Drexel H
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():5-6. PubMed ID: 18001312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
    Ballantyne CM; Davidson MH; McKenney J; Keller LH; Bajorunas DR; Karas RH
    Am J Cardiol; 2008 May; 101(10):1428-36. PubMed ID: 18471454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipokines and treatment with niacin.
    Westphal S; Borucki K; Taneva E; Makarova R; Luley C
    Metabolism; 2006 Oct; 55(10):1283-5. PubMed ID: 16979396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
    Parhofer KG
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):414-7. PubMed ID: 16151973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
    Alrasadi K; Awan Z; Alwaili K; Ruel I; Hafiane A; Krimbou L; Genest J
    Am J Cardiol; 2008 Nov; 102(10):1341-7. PubMed ID: 18993152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of prolonged-release nicotinic acid in patients treated with statins as a secondary prevention and a persistently low HDL-cholesterol level in France].
    Paillard F; Mosnier M
    Ann Cardiol Angeiol (Paris); 2008 Apr; 57(2):121-6. PubMed ID: 18394585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.